In Q1 2026, CorMedix Inc. continues to leverage its FDA-approved DefenCath antimicrobial catheter lock solution amid ongoing clinical trials for expanded patient indications while integrating its recent Melinta Therapeutics acquisition that broadens its commercial portfolio with six marketed anti-infectives. The company maintains a strong current ratio near 3.0, supporting operational scalability despite inherent risks linked to reimbursement dynamics, manufacturing dependencies, and patent litigation challenges. CorMedix’s growth is anchored on penetrating hospital and outpatient dialysis settings through multi-year supply agreements covering a majority of U.S. outpatient dialysis centers, with potential upside from new indications and synergies from the expanded infectious disease product lines.